Immage Biotherapeutics Corp. (IMMG)

Overview

Immage Biotherapeutics Corp., with its current status of having no significant business operations, has undergone a notable transformation since its inception. Founded in 2012 and originally operating under the name Epicure Charcoal, Inc., the company rebranded to Immage Biotherapeutics Corp. in June 2015. Its early mission was focused on the development of innovative immunotherapy biologics aimed at treating various cancers within the United States. Headquartered in Bethesda, Maryland, Immage Biotherapeutics has also been identified as a subsidiary of Coventry International Limited. This transition reflects a shift from its initial active engagement in cancer treatment research towards its current state.

Products and Services

Despite the current lack of significant business operations, Immage Biotherapeutics Corp.'s historical focus was on the following area:

• Development of Novel Immunotherapy Biologics: The company was previously engaged in research and development activities aimed at creating new immunotherapy treatments. These biologics were designed to mobilize the body's immune system to target and eliminate cancer cells, offering potential treatments for various types of cancer. The objective was to contribute to the existing cancer treatment modalities with innovative approaches that could offer better efficacy, lower side effects, and improved patient outcomes.